Abstract: The present study was conducted as part of an international collaborative project organized by the International Life Sciences Institute Health and Environmental Sciences Institute (ILSI-HESI project). Transgenic CB6F1 mice carrying copies of human prototype c-Ha-ras gene, CB6F1-Tg-rasH2 (rasH2) mice, were utilized as an alternative test system to a standard 2-year bioassay for carcinogenicity assessment. The antihypertensive drug reserpine, a non-genotoxic rodent carcinogen (putative non-human carcinogen), was used as a test compound for validation of these transgenic mice. Reserpine was administered to rasH2 mice at dietary concentrations of 0, 2.5, 5 and 10 ppm and to non-transgenic littermates (non-Tg) at dietary concentrations of 0 and 10 ppm for 26 consecutive weeks. The rasH2 and non-Tg mice receiving basal diet alone in the same way acted as a corresponding control. A single intraperitoneal injection of N-methyl-N-nitrosourea (MNU) to rasH2 mice served as a positive control. All surviving animals were sacrificed 26 weeks later and subjected to histopathological examination. Alveolar/bronchiolar adenoma and carcinoma of the lung, hemangiomas and hemangiosarcomas of the spleen, and papilloma of the forestomach were sporadically detected in rasH2 mice fed either the reserpine-containing diet or basal diet. No specific hyperplastic or neoplastic lesions due to reserpine were detected. In MNU-treated mice, however, thymic and/or systemic malignant lymphomas and squamous cell papilloma and/or carcinoma in the forestomach were commonly detected in both males and females with low survival rates suggesting the sensitivity of assay conditions. In conclusion, no carcinogenicity of reserpine was identified in rasH2 mice under the present experimental conditions. (J Toxicol Pathol 2004; 17: 95-103) 
Introduction
The standard rodent 2-year bioassay (two species with both sexes) has been widely used to define the carcinogenic potential of xenobiotics [1] [2] [3] [4] . At the International Conference of Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) meeting (Brussels, 1997), the regulatory agencies and pharmaceutical associations from the USA, EU, and Japan agreed with the proposal that the carcinogenic potential of pharmaceutical compounds should be evaluated by data obtained from both one long-term standard rodent and another short-or medium-term test system using transgenic (Tg), knockout, or newborn animals.
An international collaborative project under the auspices of the International Life Sciences Institute Health and Environmental Sciences Institute, ILSI-HESI, was initiated to validate the usefulness of genetically altered mouse models for carcinogenicity assessment by using 24 test compounds. The transgenic mice with v-Ha-ras (Tg. AC), CB6F1-Tg-rasH2 (rasH2), knockout for p53 +/-, or knockout for XPA -/-, as well as a neonatal mouse system have been investigated [6] [7] [8] [9] . Yamamoto et al. have reported that rasH2 mice are useful for detecting neoplastic lesions induced by genotoxic carcinogens within 6 months, and are expected to be a promising model for a rapid testing system of carcinogenicity [10] [11] [12] . The rasH2 mice originated from hemizygous Tg mice carrying five to six copies of the prototype human c-Ha-ras gene with its own promoter integrated into the genome in a tandem array. In a validation study of the short-term carcinogenicity bioassay, in which the carcinogenic potential is determined in 26 weeks, considerable data indicating the usefulness of this model have been accumulated [13] [14] [15] [16] [17] .
Reserpine is a biologically active alkaloid derived from Rauwolfia serpentia, which is prescribed for medication of hypertension. The Rauwolfia alkaloids are known to act at extremely low concentrations depleting norepinephrine in tissues; reserpine at the physiological level blocks the ATPcatalyzed uptake of norepinephrine, resulting in its sharp reduction 1, 2, 4 . Reserpine also alters the secretion of 18 . Reserpine is thought to be a non-genotoxic carcinogen, because negative results have been reported in the Ames test and a mouse lymphoma mutagenicity assay 4 . However, a positive result has been recognized in a Syrian hamster embryo cell assay 19 . In addition, the carcinogenic potential of reserpine in the mammary gland was confirmed in a 104-week bioassay with B6C3F1 mice conducted by the National Cancer Institute (Maryland, USA) 4 . The aim of the present study was to evaluate the carcinogenic potential of the antihypertensive drug reserpine, following a 26-week dietary administration to CB6F1-Tg-rasH2 (rasH2) or CB6F1-nonTg-rasH2 (nonTg) mice.
Materials and Methods

Animals
A total of 75 male and 75 female CB6F1-Tg-rasH2 (rasH2) mice and 30 male and 30 female CB6F1-nonTgrasH2 (non-Tg) mice were purchased at 6 weeks old from the Central Institute for Experimental Animals (CIEA, Kawasaki, Japan). The animals were quarantined for 1 week and then acclimatized for 1 week before use. They were housed 5 animals/cage in wire-mesh cages in an airconditioned room (temperature, 23 ± 2°C; relative humidity, 55 ± 15%) with a 12-hr light/dark cycle. Basal diet (NIH-7, Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water were available ad libitum. The animal care and experimental procedures were performed in accordance with the Guidelines for Animal Experimentation issued by the Japanese Association for Laboratory Animal Science 
Dose selection
Dose levels of reserpine were selected based on the results of a 4-week dose finding study with wild type CB6F1 mice (20 animals/group, 10, 20, or 40 ppm in diet), in which one female died at 20 ppm and all animals in both sexes died at 40 ppm. Body weights were significantly decreased at 20 ppm or more in both sexes compared with corresponding control mice. Therefore, the dose levels of 2.5, 5 and 10 ppm of reserpine, which presumably do not cause death, were selected for the present study. The selected doses were essentially identical with those of previous reports 4, 21 . The dose level of MNU was chosen from the result of previous studies 4, 21 .
Experimental design
The rasH2 mice were allocated to five groups (15/sex/ group), including the basal diet control group, positive control group given a single intraperitoneal administration of 75 mg/kg MNU, and reserpine-treated groups at doses of 2.5, 5, and 10 ppm in the diet for 26 consecutive weeks. Non-Tg mice (15/sex/group) were used as a strain-reference control and were also given the basal diet containing 0 (control) and 10 ppm of reserpine. All animals were observed for death or survival, general conditions and significant toxic signs at least once daily on weekdays throughout the study period. Palpation was done weekly at the same time as the clinical observation. The body weight and food consumption were measured weekly during the first 12 weeks and once every 4 weeks thereafter. Individual food consumption and drug intake were calculated by dividing the total amount consumed per cage by the number of animals and duration (days). All surviving animals were euthanized by exsanguination under ether anesthesia at the scheduled necropsy time, and a full internal and external macroscopic examination was performed. The animals that were sacrificed at an unscheduled time or found dead during the experiment were also subjected to full necropsy. The brain, heart, kidneys, testes/ovaries and liver were weighed and almost all tissues and organs were excised and fixed in 10% neutral buffered formalin. However, the eyes were fixed in Davidson's fixative; the testes in Bouin's fixative, and the bones were decalcified in 25% buffered formic acid. The approximately 40 organs/tissues and macroscopic lesions were embedded in paraffin wax, sectioned and stained with hematoxylin and eosin (H & E) for histopathological examination.
Statistical analyses
All numerical data are expressed as the mean ± standard deviation (SD) and were analyzed statistically. The data of food consumption, body weight and organ weight were analyzed by Dunnett's multiple comparison test or Student's t-test. Fisher's exact probability test was applied to the analysis of tumor incidences. A p value of less than 5% was considered to be significant.
Results
General observations
Four males of the 2.5 ppm group and two males and one female of the 10 ppm group died due to spontaneous neoplastic lesions during the experimental period. The first death with thymic lymphoma was noted at week 4 in one male of the 10 ppm group. In mice injected with MNU, a remarkable increase in mortality was observed (Table 1) and its major cause was considered to be the development of tumors in the hematopoietic systems and forestomach.
Significant decreases in body weights were noted at 2.5 ppm or more in male rasH2 and at 10 ppm in male non-Tg mice (Table 1) . A tendency towards a decrease in mean food consumption during the 26 weeks was observed in both males and females of the 10 ppm groups ( Table 2) . No treatment-related abnormalities were seen on clinical signs, palpable nodule, and necropsy. Mean drug intakes calculated throughout the study in rasH2 mice were 0.625, 1.240, and 2.179 mg/kg/day for males and 0.689, 1.392, and 2.533 mg/kg/day for females in the 2.5, 5, and 10 ppm groups, respectively. In non-Tg mice at 10 ppm, mean drug intake was 1.824 mg/kg/day for males and 2.112 mg/kg/day for females (Table 2) .
Organ weight
In reserpine-treated males, relative weights in the testes and brain, kidneys, and heart were significantly increased at 2.5 ppm or more, 5 ppm or more, and 10 ppm, respectively. However, increased relative liver weights were noted only at 2.5 ppm. In females, relative weights in the ovaries were significantly increased at 5 ppm or more. In non-Tg mice of both sexes, increased relative organ weights seen at 10 ppm were essentially identical to those in reserpine-treated mice (Table 3) .
Histopathology
Non-neoplastic lesions: Summarized non-neoplastic lesions are shown in Table 4 . In the reserpine-treated groups, most females treated with 5 ppm or more showed proestrus vaginal epithelia indicative of an altered estrus cycle (Fig. 1) . In the MNU group, retinal atrophy of the eye was a specific non-neoplastic lesion. Myopathy of the skeletal muscles was commonly observed in both control and treated rasH2 mice. No histopathological changes were observed in any of the organs showing significantly increased relative weights.
Neoplastic lesions: Summarized neoplastic lesions are represented in Table 5 . In rasH2 mice, neither reserpine- (14) (15) specific neoplasms nor increases in the incidence of spontaneous lesions were observed. Hemangioma and/or hemangiosarcoma of the hematopoietic systems, digestive systems, urinary systems, reproductive systems, nervous systems, and abdominal cavity were sporadically seen. Malignant lymphoma of the lymphoid organs, alveolar/ bronchiolar adenoma and carcinoma of the lung, and squamous cell papilloma and carcinoma of the forestomach, follicular cell adenoma of the thyroid, and adenoma or carcinoma of the Harderian gland were detected in a few animals in each group including the control group. These changes were considered to be spontaneous lesions frequently seen in aging native rasH2 mice. Although hemangioma of the liver was observed in one reserpinetreated rasH2 mouse, there was no occurrence of neoplastic lesions in any of the animals showing significantly increased relative organ weights. Moreover, neither proliferating nor degenerative changes were noted in the mammary gland or seminal vesicle. In the MNU-treated group, incidences of malignant lymphoma originating from the hematopoietic systems and squamous cell papilloma or carcinoma of the forestomach were significantly increased. Squamous cell papilloma of the oral mucosa, adenoma or adenocarcinoma of the intestinal tract, squamous cell carcinoma of the skin, hepatocellular carcinoma, transitional cell papilloma of the urethra, and endometrial tumor of the uterus were also seen with low incidence. MNU clearly showed carcinogenic potential in rasH2 mice.
In non-Tg mice, no reserpine-specific neoplasms or modifications of the incidence of spontaneous proliferative lesions were noted.
Discussion
In the present study, the 26-week feeding of reserpine did not induce any specific tumors or increases in incidences of spontaneous tumors in rasH2 mice or non-Tg mice. Although significantly increased relative weights of various organs were noted in reserpine-treated or non-Tg mice, no histopathological changes were observed in any of the organs examined. Therefore, this phenomenon is considered to be associated with a tendency towards a decrease in body weights, and not directly related with treatment. On the other hand, rasH2 mice treated with MNU used as a positive control showed high incidences of malignant lymphoma and squamous cell papilloma/carcinoma. These results were consistent with those of previous reports [10] [11] [12] [22] [23] [24] , which suggest that the reliability of the model was confirmed.
Altered estrus cycle and increased ovary weight seen in females given reserpine might be caused by an elevated PRL level 18 , although the levels were not measured in this study. Different from a previous report 25 , however, reserpine did not cause testicular atrophy and degeneration. According to the Boston Collaborative Drug Surveillance Program 26 and other epidemiological studies, women receiving long-term therapy with reserpine had an increased incidence of breast cancer 4, 27 . Although a considerable controversy ensured over the statistical validity of those studies, most of the clinical and experimental investigations do not support the involvement of reserpine in enhancement of mammary gland tumor growth [28] [29] [30] [31] [32] . In long-term carcinogenicity studies using B6C3F1 mice and F344 rats, which were conducted by the National Toxicology Program (NTP), dietary treatment with reserpine caused undifferentiated carcinoma (1 of 50 animals at 5 ppm and 5 of 49 animals at 10 ppm) of the seminal vesicle in male mice, mammary gland tumors (7 of 49 animals at 5 ppm, and 7 o f 4 8 a n i m a l s a t 1 0 p p m ) i n f e m al e m i c e a n d pheochromocytoma (18 of 49 animals at 5 ppm, and 24 of 48 animals at 10 ppm) in male rats 4 . With respect to genotoxicity of reserpine, negative results have been r ep orted i n the Ames test and mo use ly mpho ma mutagenicity assays 33, 34 . Reserpine, therefore, has been regarded as a non-genotoxic rodent carcinogen so far. In the Syrian hamster embryo (SHE) cell assay, however, reserpine showed positive under both 24-hour and 7-day exposure conditions 35 . According to the report from Tsutsui et al.
19
, reserpine induced a dose-related increase in morphological transformation of SHE cells. Thus, the SHE transformation was positive in spite of the fact that treatment of SHE cells with reserpine failed to induce any detectable gene mutations in two genetic assays such as chromosomal abnormalities including structural and numerical changes, and DNA adduct formations 19 . The cause of these different results still remains unclear and consequently there are some controversies regarding the relevant genotoxic potential.
As mentioned previously, the rasH2 mouse has been recognized to have high susceptibility to genotoxic carcinogens [10] [11] [12] . Additionally, this strain is thought to be a useful model for detecting non-genotoxic carcinogens as well 36 . In contrast, there are a couple of reports dealing with the low susceptibility of rasH2 mice to the carcinogen phenolphthalein (PhP). Namely, malignant lymphoma has not been apparently detected in rasH2 mice receiving PhP 37 , which was categorized as a weak or possible genotoxic carcinogen because it showed positive in chromosomal aberration and micronucleus tests, and negative in the Ames test and SHE analysis 38 . Welsch and Meites 39 have suggested that reserpine slightly accelerates the growth of 7,12-dimethylbenz[a]anthracene-induced mammary tumors by stimulating PRL secretion in female rats. In contrast, pretreatment with reserpine has been recognized to decrease the incidence of mammary tumors in rats. Similarly, Tanaka et al. 40 or Lupulescu 41 have reported that reserpine inhibits hepatocellular carcinoma or squamous cell carcinoma induced by N-2-fluorenylacetamide (FAA) or 3-methylcholanthrene (MCA). Moreover, in an alternative carcinogenicity study using p53 mice, reserpine showed no carcinogenic potential 21 . The ras oncogene has been known to play an important role in a transgenic mouse model for mammary carcinogenesis 42 . Furthermore, it has been reported that the rasH2 rat displays a high susceptibility of tumors in the mammary gland, urinary bladder, and esophageal to chemicals 43 . Therefore, the c-Ha-ras gene may contribute to carcinogenesis in the mammary gland. To our knowledge, however, there have been no reports about chemically-or spontaneously-induced mammary tumors in rasH2 mice so far 22 . Contrastingly, in a 104-week bioassay of reserpine with B6C3F1 mice, adenocarcinoma (NOS), adenosquamous carcinoma, and malignant mixed tumor in the mammary gland were confirmed 4 . This discrepancy in the carcinogenic potential between the two strains remains obscure.
Spontaneous tumors frequently seen in aging native rasH2 mice are forestomach squamous cell tumors, lung alveolar epithelial tumors and/or splenic hemangiosarcomas 7, [10] [11] [12] 22, 24, 42 . In our study, these tumors were also observed in all groups including the control mice.
In conclusion, reserpine was shown to have no carcinogenicity in rasH2 mice under the present experimental conditions. However, the validation of rasH2 mice as a model for carcinogenicity studies should be determined with further results from other compounds.
